市場調査レポート
商品コード
1215732
抗真菌剤の世界市場(2022年~2028年)Antifungal Agent Market 2022-2028 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
抗真菌剤の世界市場(2022年~2028年) |
出版日: 2023年01月14日
発行: Orion Market Research
ページ情報: 英文
納期: 2~3営業日
|
世界の抗真菌剤の市場規模は、予測期間中に3.1%のCAGRで大きく成長すると予測されています。
近年、真菌感染症は世界的に大きな健康問題となっており、院内感染の発生が市場拡大に拍車をかけています。また、がん・造血幹細胞移植の増加など、免疫系が損なわれていることが院内感染の増大に繋がり、免疫力の低下によって真菌感染症が増加し、市場拡大を促進しています。一方、真菌感染症の日常的な治療へのジェネリック医薬品・高価な医薬品の多用、抗真菌剤の重大な副作用、政府による規制が、市場拡大の妨げになる見通しです。
当レポートでは、世界の抗真菌剤市場について調査分析し、市場概要、セグメント・地域別の市場分析、競合情勢、企業プロファイルなど、体系的な情報を提供しています。
Title:Global Antifungal Agent Market Size, Share & Trends Analysis Report By Drug Class (Polyene, Echinocandins, Allylamines, and Azole), By Dosage Form (Powder, Ointment and Drugs), and By Route of Administration (Parenteral, Topical and Oral) Forecast 2022-2028.
The global antifungal agent market is anticipated to grow at a substantial CAGR of 3.1% during the forecast period. Fungal infections have become a major health concern around the globe in recent years. In addition, the occurrence of nosocomial infections is fueling market expansion. Growing cancer occurrences, an increase in hematopoietic stem cell transplantation, and other conditions that impair the immune system are all contributing to the rise of nosocomial infections. As a result of a weakened immune system, fungal infections become more common, fueling market expansion.
On the other hand, the increased availability of generic and pricey medications for the routine treatment of fungal infections is limiting the market growth. Furthermore, the market's expansion is being hampered by the substantial side effects of antifungal medications used to treat fungal infections. Government rules are projected to stifle the market's expansion. For instance, in 2020, the US FDA published guidance on the approval of antibacterial and antifungal drugs. According to the US FDA, antibacterial and antifungal drugs will only be allowed if they are meant to treat a significant life-threatening infection in a small group of patients with unmet needs.
The global antifungal agent market is segmented based on the drug class, dosage form, and routine of administration. Based on the drug class, the market is segmented into polyene, echinocandins, allylamines, and azole. Based on the dosage form, the market is sub-segmented into powder, ointment, and drugs. Based on the routine of administration the market is sub-segmented into parenteral, topical, and oral. The echinocandins category is also driving the growth of the antifungal agent market. The global antifungal medicines market is driven by an increase in the incidence of thrush, also known as oropharyngeal candidiasis, which occurs in the mouth or throat. Echinocandins are caused by the infection, the infection it causes is called candidiasis. Most can be easily treated with over-the-counter or prescription medications which increases the demand for the antifungal market.
Geographically market is segmented into: North America, Europe, Asia Pacific, and the Rest of the World. The market for antifungal medications in North America is one of the largest in the globe. The region's expansion is due to an increase in the occurrence of infectious diseases. The rise in prevalence had heightened the clinical urgency to increase the use of these medications, along with accelerating the development of novel drugs with FDA fast-track authorization. Furthermore, the presence of established pharmaceutical companies that are continually pushing for extensive marketing of their products and expanding their reach is expected to be a crucial factor driving the regional market's expansion.
The major companies serving the global Antifungal agent market include Gilead Sciences, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers &acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2021, Cadila Pharmaceuticals launched Posaconazole, a novel triazole antifungal medicine that is effective against a wide spectrum of invasive fungal illnesses. In addition, the medication has been recommended as a Mucormycosis second-line treatment.
Research Methodology
The market study of the global antifungal agent market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include:
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
The Report Covers: